Overview:
Oral cavity cancer, primarily squamous cell carcinoma (SCC), ranks among the top 10 incident cancers globally, with tobacco and alcohol as main etiological factors. Other risks include poor oral hygiene, betel nut chewing, and immune suppression. Incidence varies in Arab countries, with rates as low as 0.5/100,000 in Syria and up to 10/100,000 in Southern Saudi Arabia. In the Middle East and North Africa (MENA), oral cavity SCC (OCSCC) comprises 1.5% of all malignancies, with projected doubling of incidence and mortality rates by 2030. In Jordan, there were 97 new cases and 47 deaths due to OCSCC in 2020, with a male-to-female incidence ratio of approximately 2:1, possibly due to higher tobacco and alcohol use in males.
For resectable OCSCC, primary intervention involves surgery followed by risk-adapted postoperative radiotherapy with or without concurrent chemotherapy. Combined analysis of RTOG 9501 and EORTC 2291 trials showed benefits of concurrent chemotherapy for postoperative extranodal extension (pENE) and/or positive resection margins. Lymph node involvement is a crucial prognostic factor, along with tumor stage, surgical margins, peri-neural invasion (PNI), lymphovascular space invasion (LVI), depth of invasion, and pENE. These factors guide the need for adjuvant radiation or concurrent chemoradiotherapy.
Goal: The goal of the mini-symposium on oral cavity cancer is to provide the latest updates on a multidisciplinary treatment approach specifically targeting oral cavity cancer.
Targeted audience: This course is designed for specialists and trainees with a special focus on H&N ca, including H&N surgeons, oto-rhino-laryngologists, reconstructive surgeons, maxillofacial surgeons, radiation oncologists, medical oncologists, and other medical professionals engaged in treating patients with H&N cancer
Date and time: April 24, 2024 from 14:00-18:30 pm
Venue: King Hussein Cancer Center, Sheikh Khalifa building, third floor, Class room 4